Orion Now Has Two TEAD Trials Running. Amphista Just Showed Up With a Degrader.
Orion Pharma dosed first patients in TEADCO Phase 1b/2 basket trial of ODM-212, an oral pan-TEAD inhibitor.
Jeff Martin
Amphista Adds Two More To The Targeted Protein Degrader Playbook
Amphista Therapeutics presented AACR 2026 preclinical data for SMARCA2 and TEAD molecular glue degraders using non-cereblon ligases.
Repertoire Killed Two Cell Therapies in 2022. Now a TCR Bispecific Is in the Clinic.
Repertoire Immune Medicines dosed first patient in Phase 1/2 of RPTR-1-201, a TCR bispecific across 9 solid tumor types.
Ferrosa Raised $3.5M to Fix the Anemia Nobody Can Treat
Ferrosa Therapeutics raised a $3.5M seed to develop a first-in-class bispecific antibody for anemia of inflammation.
How These 7 Companies Are Tapping Into the Dark Side of Biotech
Four companies are mining the dark proteome for cancer targets. The same-30-targets problem may finally be cracking.
CREATE Medicines’ Mutli-Immune In-Vivo CAR Platform Enters The Clinic
CREATE Medicines dosed first patient with MT-304, a first-in-class multi-immune in vivo CAR for HER2 tumors.
Mozart Goes After CD8 Tregs. Everyone Else Targets CD4.
Mozart Therapeutics reported Phase 1b interim data for MTX-101 showing C-peptide stabilization in Stage 3 type 1 diabetes.
SAB Made Human Antibodies in Cows. Four T1D Patients Kept Their Insulin.
SAB Biotherapeutics reported Phase 1 data for SAB-142 in four established Type 1 diabetes patients.
ModeX Dosed a Tetraspecific. The T Cell Engager Field Just Got More Crowded.
ModeX Therapeutics dosed the first patient with MDX2003, a tetraspecific T-cell engaging antibody in B-cell lymphoma.
Nurix Brought Three Degraders to AACR. Two of Them Cross Into the Brain.
Nurix Therapeutics presented preclinical data on three protein degradation assets at AACR 2026.